With immune checkpoint inhibitors (ICIs) targeting programed cell death protein 1 (PD-1) and its ligand 1 (PD-L1) had achieved effect on malignant tumors, the mRNA-cancer vaccine therapy has become a hotspot in cancer immunotherapy (Pardi et al., 2018). This evidence concerns the gene PDCD1 and cancer.